Bioglutide, developed under the code NA-931, is one of the few obesity compounds chasing double-digit weight loss in a once-daily pill rather than an injection. Across its early clinical program the trials reported weight-loss figures approaching the magnitude seen in some injectable investigational agents' own trial data, and the molecule has been reported as now advancing toward Phase 3.
This article traces how those numbers built over the course of the trials — from the Phase 1 readout published in Endocrine Practice through the Phase 2 results presented at the American Diabetes Association's 2025 Scientific Sessions. It is a timeline of reported trial data, not a protocol. Bioglutide is investigational and has never been available outside a clinical trial, so there is no user or research-use experience to describe — only what the studies documented at each stage.
Research-context information only. Bioglutide (NA-931) is an investigational drug not approved by the FDA. Protocols, doses, and reactions reported below come from published clinical trials and self-reported community sources. This article reports what has been documented, not what should be done. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. Consult a licensed physician for personal medical decisions.
What Bioglutide (NA-931) Is
Bioglutide is described as an oral, once-daily quadruple agonist — a single molecule engineered to activate four receptor pathways: IGF-1, GLP-1, GIP, and glucagon. Three of those four (GLP-1, GIP, glucagon) are the same incretin-and-glucagon axis behind the injectable triple agonist retatrutide; the IGF-1 arm is the design element the trial data highlights as distinct, and the oral route is the other.
Because the trials are the only source of data on this compound, every figure below is an endpoint reported by a specific study at a specific timepoint. None of it describes what a person outside a trial would experience, and none of it is a dosing instruction.
Phase 1: The First Weight-Loss Signal (Through 12 Weeks)
The earliest human data on Bioglutide came from Phase 1 work published in Endocrine Practice. That report described approximately 10 to 13% weight loss by 12 weeks in the dosed subjects — a large early signal for a first-in-human oral candidate, and the result that justified moving the program into a larger, placebo-controlled Phase 2.
The Phase 1 number is best read as what it is: a small, early-stage readout meant to establish that the oral molecule produced a measurable weight-loss effect and was tolerable enough to advance. The 12-week window is the relevant timeline marker — the trial reported that the effect had accumulated to double digits by that point.
Phase 2: 13.8% Reported at 13 Weeks
The pivotal timeline data comes from the Phase 2 trial, registered as NCT06564753 and presented at the American Diabetes Association 2025 Scientific Sessions as late-breaking abstract 2189-LB, with related findings in abstract 143-OR. This was a 13-week, placebo-controlled study, and it is the source of the headline figure most often quoted for Bioglutide.
At the top dose of 150 mg/day, the Phase 2 abstract reported a mean 13.8% weight loss at 13 weeks. After subtracting the placebo arm, that came to roughly 12.4% placebo-adjusted — the figure that isolates the drug's own contribution from diet, expectation, and study effects. The abstract described the response as dose-dependent, meaning higher doses produced larger reported reductions across the 13-week window.
The responder data is the part that separates Bioglutide from a marginal result. The Phase 2 readout reported that 72% of subjects on the 150 mg/day arm reached at least 12% weight loss, versus about 2% on placebo. A gap that wide between the treatment and placebo arms is what the readout has leaned on in framing the compound as Phase 3-ready.
On the timeline question specifically: the trials did not publish a public week-by-week weight curve, so the honest framing is that these are endpoint means at 12 to 13 weeks, not a promised weekly rate. What the studies documented is the destination — double-digit mean loss by roughly three months — and that the effect scaled with dose along the way.
Tolerability Across the Dosing Window
For any incretin-based weight-loss compound, gastrointestinal tolerability is the factor that determines whether the reported efficacy is usable. The Phase 2 abstract characterized adverse events over the dosing period as mostly mild, reporting nausea and vomiting in roughly 7.3% and diarrhea in roughly 6.3% of subjects. The readout also reported no significant loss of lean muscle mass across the trial — a point the readout emphasized, since muscle preservation is a recurring concern with rapid weight loss.
These are trial-reported rates from a single 13-week study, not a safety profile established across large or long-duration populations. The abstract's own framing is a short, controlled trial; durability and tolerability over a full year remain Phase 3 questions.
